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Abstract
Background: Von Hippel-Lindau (VHL) disease is a rare oncological disease with an incidence of 1:36,000, and is
characterized by the growth of different types of tumors: hemangioblastomas in the central nervous system (CNS)
and retina, renal carcinoma, pheochromocytomas, pancreatic serous cystadenoma, and endolymphatic sac tumors.
These tumors do not express VHL protein (pVHL). pVHL ubiquitinates hypoxia inducible factor (HIF) protein for
degradation by the proteasome; in the absence of VHL, HIF translocates to the nucleus to activate the expression of
its target genes. Targeting VHL-derived tumors with drugs that have reduced side effects is urgent to avoid repeat
CNS surgeries. Recent reports have shown that propranolol, a β-blocker used for the treatment of hypertension and
other cardiac and neurological diseases, is the best option for infantile hemangioma (IH). Propranolol could be an
efficient treatment to control hemangioblastoma growth in VHL disease because of its antiangiogenic effects
demonstrated in IH and the hypothetical impact on HIF levels.
Methods: HeLa 9X (HRE) hypoxia responsive element cell line and primary hemangioblastoma-derived cells were
subjected to propranolol treatment and cell viability and apoptosis were evaluated. HIF1-α and Hif-2α expression
after propranolol treatment was analyzed by western blotting. Quantitative PCR was performed to study the mRNA
expression of HIF target genes. Vascular endothelial growth factor (VEGF) was measured in culture supernatants by
immunoassay.
Results: Propranolol downregulated HIF-dependent transcription in HeLa 9XHRE cells. Under hypoxic conditions,
propranolol decreased the expression of HIF target genes in hemangioblastoma cells, which stopped proliferating
and died following long-term treatment. These results suggests that propranolol treatment promoted reduced HIF
protein expression and corresponding downregulation of HIF target genes, and inhibited cell proliferation in
parallel with induction of cell death by apoptosis.
Conclusions: Our results suggest that propranolol could reduce the growth of HIF-dependent tumors and may
thus be a promising treatment to delay surgery in VHL patients.
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Background
Von Hippel-Lindau (VHL) disease is a rare type of phaco-
matosis with an incidence of 1 per 36,000 individuals in
the general population [1, 2]. The clinical manifestations
include multiple benign and malignant tumors that appear
throughout the lifespan of the patient. The most frequent
tumors are hemangioblastomas (HB) of the central ner-
vous system (CNS) and retina, and renal cell carcinoma
[3–6]. In addition, pheochromocytomas, pancreatic serous
cystadenoma, endolymphatic sac tumors and papillary
cystadenomas are associated with the disease.
VHL disease is an inherited entity, with autosomal dom-
inant transmission. Patients are heterozygous for muta-
tions in VHL, a tumor suppressor gene located on the
short arm of chromosome 3 (3p25–p26). Tumors develop
in patients who have a mutated copy of VHL at birth fol-
lowing loss of the wild-type allele (loss of heterozygosity)
[7]. Thus, the tumors of these patients either do not ex-
press VHL protein (pVHL) or the mutated form is not
functional. pVHL binds to and ubiquitinates HIF-1α and
HIF-2α to target them to the proteasome for degradation.
Therefore, in the absence of functional pVHL, HIF accu-
mulates within the cytoplasm and translocates to the nu-
cleus to trigger the hypoxia program by targeting hypoxia
responsive genes [8]. HIF-1α and HIF-2α are involved in
cell proliferation, angiogenesis, extracellular matrix deg-
radation, vascular tone, and erythropoiesis, among other
processes. All HIF target genes are normally silenced in
normoxia. pVHL cannot bind HIF in hypoxic conditions,
since prolylhydroxylases cannot hydroxylate specific pro-
line residues of HIF. In these circumstances, HIF accumu-
lates and translocates to the nucleus. Therefore, cells from
VHL tumors have a constitutively active HIF program due
to the absence of functional pVHL.
Thus far, the therapeutic options for VHL patients are
derived from surgery [9, 10]. The systemic therapy used
for metastatic cancers has shown limited response in VHL
pancreatic and renal tumors, while CNS tumors do not
respond at all. Therefore, the lack of therapies for diffuse
or recurrent disease means there is an urgent requirement
for effective drugs with reduced side effects for VHL pa-
tients, especially those that halt the progression of tumors
and subsequently delay surgical treatment. Some previous
studies have shown that propranolol, a β-blocker used for
the treatment of arrhythmia, hypertension, migraines, and
other cardiac and neurological diseases, is also the best
option for the treatment of infantile hemangioma (IH)
[11–15]. IH is the most frequent vascular benign tumor in
newborns. In the last few years, propranolol has become
the choice treatment for IH over surgery, with a long list
of publications supporting its success. In relation to this,
our group has demonstrated that endothelial cells treated
with propranolol showed decreased expression of the
pro-angiogenic proteins endoglin and ALK1, which are
HIF-1α targets [16]. Although the precise mechanism of
action of propranolol is unclear, upon blocking β-
adrenergic receptors, propranolol leads to vasoconstric-
tion (reducing the blood flow), apoptosis induction, and
inhibition of angiogenic HIF target genes such as vascular
endothelial growth factor (VEGF), fibroblast growth factor
(FGF) or metalloproteases (MMPs).
Therefore, these results led us to consider the hypothesis
that propranolol could be an efficient treatment for heman-
gioblastomas through inhibition of HIF in highly vascular-
ized tumors in which HIF is constitutively expressed.
Methods
Cell culture
HeLa 9XHRE cells were stably transfected with a HRE-
luc reporter carrying nine copies in tandem of the hyp-
oxia responsive element (HRE) followed by luciferase
gene, and were cultured in DMEM (Dulbecco’s Modified
Eagle Medium, Gibco, Grand Island, NY, USA) supple-
mented with 10 % fetal bovine serum (FBS; Gibco),
2 mM L-glutamine and 100 U/ml penicillin/strepto-
mycin (Gibco). To induce hypoxic conditions, HeLa cells
were cultured either with 100 μM desferrioxamine
(DFO) (chemical hypoxia) or incubated in a hypoxic
chamber (Billups-Rothemberg, Inc, Del Mar, CA) in 1 %
oxygen, 5 % CO2 and 94 % N2, for 24 h.
Primary cultures of CNS hemangioblastoma were ob-
tained according to the previously novel protocol designed
by Serrano-Heras and scientific collaborators from Gen-
eral University Hospital of Albacete, Spain (Manuscript in
preparation). Between March 2013 and march 2014 clin-
ical samples from 4 patients (3 men and 1 woman, mean
range 31.5 ± 15.6 years, and range: 13–45) diagnosed of
Von Hippel-Lindau disease were taken collected from the
Neurosurgery department at “Fundación Jiménez Díaz”,
Universitary Hospital, Spain. Prior informed consent writ-
ten forms were obtained from all patients. All procedures
had been previously approved by the Ethics Committee in
accordance with general accepted guidelines for human
samples. The collected fresh tissue from the excess of
resected hemangioblastoma was placed in sterilized tubes
containing ice-cold Earle’s Balanced Salt Solution (EBSS,
Gibco). Tumor samples were washed several times with
PBS, and cut into 1 mm3 pieces. Tissue pieces were
transferred with sterile tweezers to clean cell culture dishes
(Sarstedt, Germany) and subjected to enzymatic digestion
with equal amount of collagenase I and dispase II to a final
concentration of 1 mg/m in EBSS, for 45 min at 37 °C.
After that, the pieces were completely disaggregated by
gently pipetting and digested for 15 min with trypsin at
37 °C. Then, minced samples were centrifuged, cell pellets
were suspended in growth medium (RPMI 1640 (Gibco)
supplemented with 20 % fetal bovine serum, 1 % Pen/Strep
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and 4 mM of glutamine), and incubated at 37 °C. Medium
was replaced every 72 h until the cultures were confluent.
Furthermore, Flow Cytometry was performed for cell
characterization. The analysis showed that cultures were
composed of stromal cells (30–50 % CD99 + cells), endo-
thelial cells (15–25 % CD34+ cells), and pericytes (30–40 %
NG2+ cells). The experiments were performed in all types
of cells composing the hemangioblastoma. A total of
four hemangioblastomas from different patients were
assayed in culture, with the following localization:
HB2, spinal bulb; HB3, temporal lobe; HB7, spinal
cord; HB11, temporal lobe.
Real-time RT-PCR
Total cellular RNA was extracted from hemangioblastoma
cells using a Nucleo Spin RNA kit (Macherey-Nagel,
Düren, Germany). One microgram of total RNA was
reverse-transcribed in a final volume of 20 μl with the First
Strand cDNA Synthesis Kit (Roche, Mannheim, Germany)
using random primers. SYBR Green PCR system (BioRad,
Hercules, CA, USA) was used to carry out real-time PCR
with an iQ5 system. The sequences of the oligonucleotides
used corresponded to HIF-1α and -2α target genes, as fol-
lows: VEGF forward: 5’-ATCTGAGCAGGGCGACAGC-3’
and reverse 5’-ACTCCCTGTGGTGCAGTCA-3’; EPO
forward 5’-TGTTTTCGCACCTACCATCA-3’ and reverse
5’-AAGTCACAGCTTGCCACCT-3’; and SOX2 forward
5’-GGGGGAATGGACCTTGTATAG-3’ and reverse 5’-
CGCTCCACCAACTAAGAACG-3’. As an internal con-
trol, mRNA levels of 18S were measured using the
following primers: forward 5’-CTCAACACGGGAAAC
CTCAC-3’ and reverse 5’-CGCTCCACCAACTAAGAA
CG-3’. Amplicons were detected using an iQ5 system
(BioRad). The samples were used in triplicate and the
experiment was repeated twice.
Western blot analysis
Cells were lysed on ice for 30 min in TNE buffer (Tris
50 mM NaCl 150 mM-EDTA 1 mM 0.5 % Triton X100)
supplemented with protease inhibitors (Complete Roche
Diagnostics) and lactacystin as a specific proteasome inhibi-
tor to preserve HIF. Lysates were centrifuged at 14,000 × g
for 5 min. Similar amounts of proteins from aliquots of
cleared cell lysates were boiled in SDS sample buffer
and analyzed by 10 % SDS-PAGE under non-reducing
conditions. Proteins from gels were electrotransferred to
nitrocellulose membranes followed by immunodetection
with anti-HIF1α (BD, Bedford, MA, USA), anti-HIF-2α
(NOVUS, Oxon, UK) and anti-γ-tubulin (Sigma, St.Louis,
MO, USA) antibodies at the dilution recommended by the
manufacturer. Secondary antibodies were horseradish
peroxidase conjugates from Dako (Glostrup, Denmark).
Membranes were developed by chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate,
Thermo Scientific, Rockford, IL, USA).
Luminescent cell viability assay
The viability of hemangioblastoma and HeLa 9X HRE
cells was measured with a CellTiter-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI, USA). This
is a homogeneous method to determine the number of
viable cells in culture based on quantitation of the ATP
present, which signals the presence of metabolically ac-
tive cells. A total of 10,000 cells were plated in 96-well
plates and cultured for 24 h and 48 h with propranolol
(50 μM and 100 μM) in 100 μl of medium. After treat-
ment, plates were equilibrated to room temperature for
30 min before the addition of 100 μl of Cell Titer-Glo
reagent (Lysis buffer, Ultra-Glo Recombinant Luciferase,
Luciferine and Mg2+). Cell lysis was induced in an
orbital shaker for 2 min, and then plates were incubated
at room temperature for 10 min to stabilize the lumines-
cent signal. Luminescence was measured using a Glomax
Multidetection System (Promega).
Caspase activation assay
The Caspase-Glo 3/7 Assay (Promega) is a lumines-
cent assay that measures caspase-3 and caspase-7 ac-
tivity using a luminogenic caspase-3/7 substrate that
contains the tetrapeptide sequence DEVD in a reagent
optimized for caspase activity, luciferase activity and
cell lysis. Luminescence is proportional to the amount
of caspase activity present. A total of 10,000 heman-
gioblastoma cells were plated in 96-well plates and
cultured for 24 h and 48 h with propranolol (50 μM
and 100 μM) in 100 μl of medium. After treatment,
plates were equilibrated to room temperature for
30 min before the addition of 100 μl of Caspase Glo
3/7 Reagent (lysis buffer, Ultra-Glo Recombinant Lu-
ciferase, DEVD-aminoluciferine and Mg2+). Cell lysis
was induced by shaking for 30 s (300 rpm), and then
plates were incubated at room temperature for 2 h.
Luminescence was measured using a Glomax Multi-
detection System (Promega).
VEGF determination in plasma
A Quantikine Human VEGF ELISA kit from R&D
Systems (Abingdon, UK) was used to quantitatively
determine human VEGF-A concentration in superna-
tants of hemangioblastoma culture cells treated with
propranolol at different doses.
Statistics
Data represent mean ± SD. Differences in mean values
were analyzed using the Student’s t-test. P-values of
<0.05 were considered to be statistically significant;
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statistically significant values are marked with asterisks
(*P < 0.05; **P < 0.01; ***P < 0.005).
Results
Propranolol downregulates HIF-dependent transcription
in 9XHRE HeLa cells
HeLa cells stably transfected with HRE-luc reporter were
used to measure HIF-dependent transcription (Fig. 1a).
Hypoxia activation was measured quantitatively by a
luminometry assay under hypoxic conditions. When
HeLa cells were subjected to chemical hypoxia (100 μM
DFO), a marked increase in luciferase units, over nor-
moxic conditions, of up to 3.5 fold was detected.
However, treatment of the cells in hypoxic conditions
with 50 and 100 μM propranolol counteracted the hyp-
oxic stimulation of HeLa 9XHRE cells, as shown by a
decrease in luciferase activity (Fig. 1b). The results were
statistically significant in all cases, with the exception of
those obtained under normoxia and for treatment with
50 μM propranolol (P < 0.005). Culture of cells in a
hypoxic chamber (1 % O2) with or without propranolol
yielded essentially the same results as with DFO (data
not shown).
Propranolol decreases the expression of HIF target genes
in hemangioblastoma cells
Next, we explored the effects of propranolol treatment
of hemangioblastoma cells over HIF targets. Thus, the
expression of genes transcriptionally regulated by HIF-
1α, such as VEGF and EPO (erythropoietin), and HIF-
2α, such as SOX2 (SRY-related HMG BOX) was studied
by quantitative RT-PCR. As shown in Fig. 2a, the levels
of transcripts of all these genes were significantly
decreased by 40–60 % from a dose of 50 μM. The levels
of EPO and SOX2 were reduced in a dose-dependent
manner; at 100 μM propranolol, the level of the different
mRNAs was about 40 % of the controls. These results
were observed in all four hemangioblastomas samples.
The results agree with a lower transcription level of HIF
target genes. Notably,VEGF and EPO are HIF-1α targets
involved in angiogenesis and oxygen supply to cells,
while SOX2 is a transcriptional target of HIF-2α and is a
stemness target implicated in the undifferentiated nature
of the mesenchymal component predominant in heman-
gioblastomas [17-19].
VEGF, one of the main targets of HIF-1α, and a potent
mediator of both angiogenesis and vasculogenesis, was
also measured in the supernatants of two different
hemangioblastoma samples cultured with and without
propranolol. As observed in Fig. 2b, the levels of VEGF
were decreased by treatment with 50 μM propranolol, in
agreement with the mRNA results (Fig. 2a).
Propranolol affects the viability of tumor cells and
induces cell death by apoptosis
Albiñana et al. (2012) reported that propranolol induces
apoptosis and decreases viability of human endothelial
and EOMA cells (murine hemangioendothelioma endo-
thelial cells) [16, 20]. Viability of HeLa cells after DFO
treatment (chemical hypoxia), with and without propran-
olol, was quantitatively measured using the CellTiter-Glo
luminescent cell viability assay. As shown in Fig. 3a,
propranolol treatment affected the viability of HeLa cells.
On the other hand, when apoptosis was measured quanti-
tatively with the Caspase-Glo 3/7 luminescent assay, it
was found that propranolol reduces viability of HeLa cells
through an increase in apoptosis by caspase 3/7 activation.
After 48 h propranolol treatment, cells stopped proliferat-
ing, and the increase in caspase activity promoted cell
death (Fig. 3b).
Next, we used the same assays to check survival and
apoptosis of hemangioblastoma cells after propranolol
treatment for 24 and 48 h. Figure 4 shows viability, cas-
pase 3/7 activation, and the caspase activation/viability
ratio in the four hemangioblastoma cultures from four
different VHL patients; viability decreased with propran-
olol in a concentration- and time-dependent manner in
almost all cases. Here, each hemangioblastoma repre-
sents a different culture from a different patient and
different tumor, therefore there is wide variability, but
we show in all cases that the response is qualitatively
similar. The lowest viabilities were found after treatment
with 100 μM of propranolol for 48 h. This decrease in
Fig. 1 Propranolol downregulates HIF-dependent transcription in HeLa
cells. a Schematic structure of 9XHRE-luc reporter. b HIF-dependent
transcription in HeLa reporter cell line. Luciferase assays were
performed in HRE-luc-stably transfected HeLa cells under hypoxic
conditions and propranolol treatment. Propranolol (50–100 μM)
prevented hypoxia stimulation in HeLa cells, as shown by the decrease
in luciferase activity, by inhibiting the activation of hypoxia elements
(HRE) by HIF. ***P < 0.005
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viability can be explained by an increase in apoptosis
through caspase 3/7 activation, particularly at 100 μM
and after 48 h of treatment.
Given the previous results of viability reduction and
apoptosis induction after propranolol treatment, we de-
cided to subject hemangioblastoma cells to long-term
propranolol treatment, starting with 50,000 cells per
well, and recording images in a time course follow-up.
As shown in Fig. 5, hemangioblastoma cells appeared to
stop proliferating, and then an increase in cell death is
detected since there were empty spaces in the plates.
The death, as explained by the previous results (Fig. 4),
must be attributed to apoptosis. After 5 days (96 h) of
continuous propranolol treatment, there were few cells
remaining in the 100 μM propranolol-treated cultures,
with fewer than 5,000 cells with poor morphology,
compared with 300,000 healthy cells in the untreated
cultures. The remaining propranolol-treated cells, on the
other hand, exhibited an atypical and apoptotic
appearance.
Altogether, we can conclude that propranolol de-
creases the viability of tumor cells (HeLa and VHL-
Fig. 2 Propranolol decreases the expression of HIF target genes in hemangioblastoma cells. a The transcription levels of HIF target genes, VEGF,
EPO and SOX2, were compared with the endogenous control of 18S ribosomal RNA. Propranolol treatment led to a dose-dependent decrease in
mRNA expression as a consequence of the reduced expression of HIF targets. Differences were statistically significant according to the Student’s
t-test. *P < 0.05; **P < 0.01; ***P < 0.005. b VEGF soluble levels were measured by ELISA assay in supernatants of hemangioblastoma cultures
treated with propranolol. Soluble VEGF levels were decreased in propranolol-treated cells compared with untreated ones
Fig. 3 Propranolol affects viability and caspase activation in HeLa cells. HeLa 9XHRE cells were cultured in the absence or presence of propranolol
(50 μM or 100 μM). Viability was measured using a CellTiter-Glo assay (a), and apoptosis was measured using a Caspase-Glo 3/7 assay (b). The his-
tograms show an increase in the activation of caspase 3/7 and a reduction in cell viability
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Fig. 4 Propranolol affects viability and caspase activation in hemangioblastoma cells. Different lines of hemangioblastoma cells were cultured in
the absence or presence of propranolol (50 μM or 100 μM) to measure viability and apoptosis. The histograms show a decrease in viability (a),
with a parallel increase in the activation of caspase 3/7 (b). Finally, in relation to the decreased cell viability, the ratio of apoptosis vs. viability is
shown (c). Propranolol promoted a decrease in viability by increasing apoptosis in these tumor cells
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Fig. 5 Long-term propranolol treatment inhibits proliferation and promotes death of hemangioblastoma cells. Time course of propranolol treatment.
Hemangioblastoma cells were treated at different doses (50 μM and 100 μM) and for varying lengths of time (from 24 h to 96 h) with propranolol.
Significant changes in morphology in treated cells were observed at 100 μM, while at 50 μM the cells exhibited the same morphology as the control
cells but with characteristic nucleoli. After 96 h with 100 μM treatment, most cells had disappeared from the plate as a consequence of cell death by
apoptosis (Magnification 40X)
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derived hemangioblastoma cells) by stopping prolifera-
tion and inducing cell death by apoptosis. This result
would be compatible with the regression observed in IH,
and it would suggest that propranolol could delay the
proliferation of hemangioblastomas in VHL patients.
Hemangioblastomas have a heterogeneous cell compos-
ition consisting of pericytes, stromal and endothelial cells.
Propranolol affects all cell types. As a complementary re-
sult, Fig. 6 also supports the loss of migration and angio-
genic activity of hemangioblastoma cells after propranolol
treatment. In fact, propranolol treatment prevents the
tubulogenesis displayed by the hemangioblastoma cells in
matrigel. The endothelial/pericyte cells of hemangioblas-
tomas display a typical network arrangement in special
culture conditions such as matrigel. Thus, hemangioblas-
toma cells without propranolol treatment tend to build
“tube-like structures of cells”, while propranolol abrogates
this manifestation of in vitro angiogenesis.
Discussion
Von Hippel-Lindau (VHL) is an autosomal dominant dis-
ease that results in many highly vascularized tumors dis-
seminated over the body. VHL is an age-dependent and
highly penetrant disease, and the more common manifes-
tations include retinal and CNS hemangioblastomas, clear
cell renal carcinomas, pheochromocytomas, and endolym-
phatic sac tumors of the middle ear [21, 22]. The mechan-
ism for the pathogenesis of VHL disease is explained by
the two-hit hypothesis [23]. One allele of VHL is usually
an inherited mutant copy while the second hit is acquired
through somatic mutation or hypermethylation. Tissue
microdissection has showed VHL gene deletion in the
stromal cells of hemangioblastomas [24], indicating that
stromal cells are the true tumor cells derived from
embryologically arrested hemangioblasts that are able to
develop into hematopoietic and endothelial progenies
under suitable conditions [2]. VHL is a complicated
systemic disease with serious involvement throughout the
entire body. Currently, there is no cure, nor successful
therapeutic options, except surgery to remove the VHL
tumors. Therefore, there is a need for drugs to target
tumour growth to delay or remove the need for surgery.
VHL tumors express HIF1α and HIF2α in a constitutive
manner [17, 18] since they lack functional pVHL. HIF is a
transcription factor that can activate hundreds of target
genes involved in angiogenesis, tumor formation, survival,
invasion, and metabolism [25–27]. Given that tumors
from VHL patients lack functional pVHL, HIF is constitu-
tively expressed in normoxic conditions, as corroborated
by the high levels of HIF detected in these tumors by
western blotting (Fig. 7). This is in contrast with HeLa
cells under normoxic conditions where there is no HIF
protein, unless subjected to hypoxic conditions, as previ-
ously reported [28]. Hence, a drug targeting HIF, and thus
the genes it regulates, would be the ideal strategy to delay
VHL tumor progression.
It has been suggested that propranolol may act through
different ways, including vasoconstriction, as an anti-
angiogenic inhibiting VEGF production, and as a pro-
apoptotic drug leading to cell apoptosis [11, 20, 29, 30].
However, its potential therapeutic benefits in different vas-
cular anomalies remain to be explored.
Based on previous results of propranolol efficiency for
IH treatment [12–15], and our own results showing that
propranolol acts as antiangiogenic in endothelial cells by
decreasing transcription levels of proangiogenic factors
such as endoglin and ALK1 [16], we hypothesized that
propranolol could act by decreasing HIF levels and
therefore downregulating the HIF target program. As a
putative side effect of propranolol treatment, concerns
about long-term neurodevelopmental or cognitive effects
of propranolol have recently arisen after a study by
Langley and Pope [31]. These authors argue that pro-
pranolol can cross the blood–brain barrier and can
cause sleep and memory disturbances, as demonstrated
by decreased specific memory functions in adults. This
work was commented upon by Tozzi [32] in a letter to
the Editor, and Léauté-Labrèze et al. responded [33] in
the same issue of the journal. The reply is supported,
first of all, by the lack of adverse events in children
treated with propranolol. In fact, the rates of neuro-
developmental defects or delay observed among 272
propranolol-treated children from 2008 to 2013 seem to
be within the range observed in the normal population.
Fig. 6 Propranolol inhibits angiogenesis. Treatment with propranolol inhibits tubulogenesis of hemangioblastoma cells partially (50 μM) or
completely (100 μM). (Magnification, 40X)
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On the other hand, the article by Langley and Pope is
essentially theoretical and not evidence-driven, and
includes data from small studies in healthy adults.
Interestingly enough, all the HIF target genes, including
among others, VEGF, MMPs, EPO or FGF, are absolutely
necessary for the survival and progression of tumors in
general, and for hemangioblastomas in particular. Heman-
gioblastomas are complex tumors consisting of different
cellular types, with stromal (undifferentiated mesenchymal
cells) and endothelial cells as the main components. Thus
being so, propranolol might be able to stop vascular
dependent growth of hemangioblastomas [2, 34].
In the present work, we have shown that propranolol
downregulates HIF-1 targets. In fact, propranolol inhibited
HIF-dependent transcription in a 9xHRE HeLa reporter cell
line (Fig. 1) and the crucial gene targets for hemangio-
blastoma survival, such as VEGF, EPO and SOX2 (Fig. 2).
EPO has been reported to be active in hemangioblastoma
tumorlets of VHL patient [35–37], and according to Fig. 2a
its expression was reduced by almost half in the presence of
propranolol. On the other hand, VEGF was shown to be
downregulated at the transcriptional level (Fig. 2a), but also
as protein secreted into the culture supernatants of different
hemangioblastomas cultivated in vitro (Fig. 2b). Moreover,
the impaired angiogenesis of hemangioblastomas in matri-
gel is shown in Fig. 6, where the tubular network of
untreated cells remained with unclosed cells at an inter-
mediate dose of propranolol, and its formation was pre-
vented at the highest propranolol dose. This is in agreement
with the results obtained by Albiñana et al. (2012) where
propranolol precluded the tube formation of treating
EOMA and human endothelial cells at the highest dose.
Hemangioblastoma tissue is composed of neoplastic stro-
mal cells and abundant reactive vascular cells [19, 24, 38].
VHL-deficient tumor cells have hemangioblastic differenti-
ation capacity [39, 40]. Stromal cells are undifferentiated
cells of mesenchymal nature, where SOX-2 master stem-
ness marker is expressed as a HIF-2α target. Thus, we
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Fig. 7 HIF-1α and HIF-2α protein expression is decreased following propranolol treatment. a Western blot assays were performed on lysates from
9XHRE HeLa cells. In agreement with luciferase assays, there were no differences in HIF-1α and HIF-2α protein levels between the different
propranolol treatments under normoxia. After DFO treatment (simulating hypoxia), levels of both proteins increased. When propranolol was
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explored the expression of SOX-2 in hemangioblastoma be-
fore and after propranolol treatment, and SOX-2 levels
were also significantly decreased by propranolol (Fig. 2).
We established that propranolol decreased HIF-
dependent transcription in 9XHRE HeLa cells under
hypoxia and in hemangioblastoma cells constitutively
expressing HIF, as shown in Fig. 7a, the amounts of HIF1α
and HIF2α protein under hypoxic conditions in HeLa cells
were decreased by propranolol treatment. This fact was
also tested in hemangioblastoma cells that were function-
ally hypoxic, as shown by the expression of HIF1α and
HIF2α under normal culture conditions. Western blotting
demonstrated that both HIF-1α and 2α were decreased by
propranolol treatment at the protein level (Fig. B).
Next, we explored whether propranolol could interfere
with proliferation and survival of hemangioblastoma cells.
As HIF triggers the hypoxia gene program to maintain cell
survival, the previous results suggested that propranolol
also affected cell viability. In fact, Fig. 3 demonstrates that
propranolol reduced the viability of HeLa cells under
hypoxic conditions. The cause of death was determined to
be apoptosis, as measured by the activity of caspases 3/7,
Fig. 8 Hypothetical model of propranolol mechanism of action
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which was increased by three-fold over untreated cells at
the highest dose of propranolol. Interestingly, the same
holds true when the viability and apoptosis of hemangio-
blastoma cells from different VHL patients were evaluated
after propranolol treatment. Figure 4 shows that heman-
gioblastoma cell viability may drop by up to 50 % after
48 h, and that apoptosis is increased between 2.5- and
5-fold following 48 h of 100 μM propranolol treatment.
Given these results, our assumption was that, if
propranolol treatment was sustained in time, cells
would disappear as is shown in Fig. 5 in hemangio-
blastoma cells. Notably, after 96 h at 100 μM pro-
pranolol treatment, very few cells remained attached
to the wells, and those that remained alive had an
extremely thin and elongated shape, showing the
appearance of apoptotic cells.
Altogether, the results suggest that propranolol first
decreases HIF levels in hemangioblastoma cells, and in
this way, the HIF targets are partially silenced/decreased.
Consequently, in the absence of essential factors for sur-
vival, the tumor cells, stop dividing and die by apoptosis.
A scheme showing the hypothetical mechanism of action
of propranolol investigated in the present paper is
presented in Fig. 8.
Conclusions
In conclusion, our results suggest that propranolol re-
duces the growth of HIF-dependent tumors, and may
be a promising therapeutic drug to delay surgery in
VHL patients.
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